BA3011 for advanced solid tumors

BA3011 for advanced solid tumors

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description

This study involves taking a study drug called BA3011. Theoverall goal of this study is to see if BA3011 is a possible treatment forpatients with sarcoma.

Eligibility and criteria
IRB Number:
21-019142
Eligible age range:
12 years - 30 years
Clinical trial phase:
Phase I
Phase II
Official title:
BA3011-001: A Phase 1/2 Dose Escalation And Dose Expansion Study Of BA3011 Alone And In Combination With Nivolumab In Adult And Adolescent Patients 12 Years And Older With Advanced Solid Tumors

What to expect

The purpose of this study is to evaluate the safety and tolerability in the study drug, BA3011. This study will enroll patients 12 years of age and older that have been diagnosed with advancedsarcoma that hasn’t responded to other treatments. The overall goal of thisstudy is to see if BA3011 is a possible treatment for patients with sarcoma.Subjects will receive BA3011 either alone or in combination with Nivolumab.  Both areadministered via IV infusion. Study visits include the following assessments:blood draws, electrocardiograms (ECGs), and tissue collection (if a tumorbiopsy is performed as part of regular clinical care). Reimbursement for travelmay be provided.

 

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.